U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

You may have been too young to remember, but depending on your state’s school immunization requirements, you likely received ...

RSV rates can be expected to increase, and flu, as well as other common viruses. Human metapneumovirus tends to peak in ...

Despite the Centers for Disease Control and Prevention's recommendations, vaccine rates against COVID-19, RSV, and the flu ...

In addition to vaccinations, Shah emphasizes the importance of avoiding gatherings when you do not feel well and shares an ...

Infections caused by the latest variant have symptoms including fever, chills, fatigue, cough, congestion and headache.

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...